Skip to main navigation Skip to search Skip to main content

PDL1 Regulation by p53 via miR-34

  • Maria Angelica Cortez
  • , Cristina Ivan
  • , David Valdecanas
  • , Xiaohong Wang
  • , Heidi J. Peltier
  • , Yuping Ye
  • , Luiz Araujo
  • , David P. Carbone
  • , Konstantin Shilo
  • , Dipak K. Giri
  • , Kevin Kelnar
  • , Desiree Martin
  • , Ritsuko Komaki
  • , Daniel R. Gomez
  • , Sunil Krishnan
  • , George A. Calin
  • , Andreas G. Bader
  • , James W. Welsh

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Although clinical studies have shown promise for targeting PD1/PDL1 signaling in non-small cell lung cancer (NSCLC), the regulation of PDL1 expression is poorly understood. Here, we show that PDL1 is regulated by p53 via miR-34. Methods: p53 wild-type and p53-deficient cell lines (p53-/- and p53+/+ HCT116, p53-inducible H1299, and p53-knockdown H460) were used to determine if p53 regulates PDL1 via miR-34. PDL1 and miR-34a expression were analyzed in samples from patients with NSCLC and mutated p53 vs wild-type p53 tumors from The Cancer Genome Atlas for Lung Adenocarcinoma (TCGA LUAD). We confirmed that PDL1 is a direct target of miR-34 with western blotting and luciferase assays and used a p53R172HΔg/+K-rasLA1/+ syngeneic mouse model (n = 12) to deliver miR-34a-loaded liposomes (MRX34) plus radiotherapy (XRT) and assessed PDL1 expression and tumor-infiltrating lymphocytes (TILs). A two-sided t test was applied to compare the mean between different treatments. Results: We found that p53 regulates PDL1 via miR-34, which directly binds to the PDL1 3' untranslated region in models of NSCLC (fold-change luciferase activity to control group, mean for miR-34a = 0.50, SD = 0.2, P <. 001; mean for miR-34b = 0.52, SD = 0.2, P =. 006; and mean for miR-34c = 0.59, SD = 0.14, and P =. 006). Therapeutic delivery of MRX34, currently the subject of a phase I clinical trial, promoted TILs (mean of CD8 expression percentage of control group = 22.5%, SD = 1.9%; mean of CD8 expression percentage of MRX34 = 30.1%, SD = 3.7%, P =. 016, n = 4) and reduced CD8+PD1+ cells in vivo (mean of CD8/PD1 expression percentage of control group = 40.2%, SD = 6.2%; mean of CD8/PD1 expression percentage of MRX34 = 20.3%, SD = 5.1%, P =. 001, n = 4). Further, MRX34 plus XRT increased CD8+ cell numbers more than either therapy alone (mean of CD8 expression percentage of MRX34 plus XRT to control group = 44.2%, SD = 8.7%, P =. 004, n = 4). Finally, miR-34a delivery reduced the numbers of radiation-induced macrophages (mean of F4-80 expression percentage of control group = 52.4%, SD = 1.7%; mean of F4-80 expression percentage of MRX34 = 40.1%, SD = 3.5%, P =. 008, n = 4) and T-regulatory cells. Conclusions: We identified a novel mechanism by which tumor immune evasion is regulated by p53/miR-34/PDL1 axis. Our results suggest that delivery of miRNAs with standard therapies, such as XRT, may represent a novel therapeutic approach for lung cancer.

Original languageEnglish
Article numberdjv303
JournalJournal of the National Cancer Institute
Volume108
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Dive into the research topics of 'PDL1 Regulation by p53 via miR-34'. Together they form a unique fingerprint.

Cite this